Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rxsight Inc (RXST)

Rxsight Inc (RXST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 403,358
  • Shares Outstanding, K 41,117
  • Annual Sales, $ 139,930 K
  • Annual Income, $ -27,460 K
  • EBIT $ -45 M
  • EBITDA $ -51 M
  • 60-Month Beta 1.14
  • Price/Sales 2.81
  • Price/Cash Flow N/A
  • Price/Book 1.46

Options Overview Details

View History
  • Implied Volatility 273.97% (-44.02%)
  • Historical Volatility 66.35%
  • IV Percentile 92%
  • IV Rank 62.64%
  • IV High 408.96% on 10/29/25
  • IV Low 47.68% on 03/17/25
  • Expected Move (DTE 33) 2.96 (30.15%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 108
  • Volume Avg (30-Day) 137
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 4,354
  • Open Int (30-Day) 3,362
  • Expected Range 6.85 to 12.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.43
  • Number of Estimates 3
  • High Estimate -0.32
  • Low Estimate -0.62
  • Prior Year -0.15
  • Growth Rate Est. (year over year) -186.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.64 +13.54%
on 01/09/26
13.14 -25.35%
on 12/17/25
-2.95 (-23.12%)
since 12/16/25
3-Month
7.99 +22.78%
on 11/05/25
13.22 -25.79%
on 12/11/25
+1.33 (+15.68%)
since 10/16/25
52-Week
6.32 +55.22%
on 07/09/25
34.71 -71.74%
on 02/04/25
-21.37 (-68.54%)
since 01/16/25

Most Recent Stories

More News
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer

ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following...

RXST : 9.81 (+0.20%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST).  Such investors are advised to...

RXST : 9.81 (+0.20%)
RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference

ALISO VIEJO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery,...

RXST : 9.81 (+0.20%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST

NEW YORK , Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST).  Such investors are advised to...

RXST : 9.81 (+0.20%)
RxSight, Inc. Announces Chief Financial Officer Transition

ALISO VIEJO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery,...

RXST : 9.81 (+0.20%)
RxSight, Inc. to Present at the Piper Sandler Healthcare Conference

ALISO VIEJO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – November 20, 2025  – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision...

RXST : 9.81 (+0.20%)
RxSight, Inc. Reports Third Quarter 2025 Financial Results

ALISO VIEJO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following...

RXST : 9.81 (+0.20%)
RxSight, Inc. to Report Third Quarter 2025 Financial Results on November 5, 2025

ALISO VIEJO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) –  RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following...

RXST : 9.81 (+0.20%)
RxSight, Inc. to Feature Live Learning Sessions at American Academy of Ophthalmology 2025 Annual Meeting

ALISO VIEJO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following...

RXST : 9.81 (+0.20%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RxSight, Inc. of Class Action Lawsuit and Upcoming Deadlines - RXST

NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against RxSight, Inc. ("RxSight" or the "Company")(NASDAQ: RXST). Such investors...

RXST : 9.81 (+0.20%)

Business Summary

RxSight Inc. is a commercial-stage medical technology company focuses on patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens(R), RxSight Light Delivery Device and accessories. RxSight Inc. is based in ALISO VIEJO, Calif.

See More

Key Turning Points

3rd Resistance Point 10.66
2nd Resistance Point 10.41
1st Resistance Point 10.11
Last Price 9.81
1st Support Level 9.56
2nd Support Level 9.31
3rd Support Level 9.01

See More

52-Week High 34.71
Fibonacci 61.8% 23.87
Fibonacci 50% 20.51
Fibonacci 38.2% 17.16
Last Price 9.81
52-Week Low 6.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar